Brief: Bausch + Lomb And Clearside Biomedical Announce The U.S. Commercial Launch Of Xipere
28/03/2022 12:05
March 28 (Reuters) - Bausch Health Companies Inc BHC.TO :
* BAUSCH + LOMB AND CLEARSIDE BIOMEDICAL ANNOUNCE THE U.S.
COMMERCIAL LAUNCH OF XIPERE® (TRIAMCINOLONE ACETONIDE INJECTABLE
SUSPENSION) FOR SUPRACHOROIDAL USE FOR THE TREATMENT OF MACULAR
EDEMA ASSOCIATED WITH UVEITIS
Source text for Eikon: ID:nPn3Z8wWHa
Further company coverage: BHC.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clearside Biomedical,
See all newsBrief: Clearside Biomedical Completes Financial Restructuring And Emerges From Chapter 11 With Steel Partners As Plan Sponsor
U.S. STOCKS ON THE MOVE-Merck, Genco, Tesla
U.S. STOCKS ON THE MOVE-Morgan Stanley, Merck, Genco
Clearside Biomedical plunges after filing for Chapter 11 bankruptcy
U.S. STOCKS ON THE MOVE-Bristol Myers Squibb, Palo Alto Networks, MP Materials